Full Press Release Details
Vicarious Surgical Announces Launch of Proposed
WALTHAM, Mass, August 2, 2023 - Vicarious
Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE: RBOT, RBOT WS), a next-generation robotics technology
company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has
commenced an underwritten public offering of $45.0 million of shares of its Class A common stock ("Common Stock"). All of
the shares of Common Stock are being offered by Vicarious Surgical. In addition, the Company has granted the underwriters a 30-day option
to purchase up to $6.75 million of additional shares of its Common Stock.
Morgan Stanley & Co. LLC and Cowen and Company,
LLC are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Vicarious Surgical intends to use the net proceeds
from the offering, together with its existing cash and cash equivalents, for funding of ongoing operations, including the development
of our single-port surgical robot, called the Vicarious Surgical System, and other general corporate purposes.
A registration statement on Form S-3 relating
to these securities was filed with the Securities and Exchange Commission ("SEC") on October 7, 2022, and
was declared effective by the SEC on October 27, 2022. The offering is being made only by means of a preliminary prospectus
supplement and accompanying prospectus which will be filed with the SEC relating to and describing the terms of the proposed offering
and will be available on the SEC's website at www.sec.gov. You can also obtain the preliminary prospectus supplement and accompanying
prospectus, when available, by contacting Morgan Stanley & Co. LLC at Morgan Stanley & Co. LLC, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 1-866-718-1649 or by email at prospectus@morganstanley.com,
or Cowen and Company, LLC at Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com or
by telephone at (833) 297-2926. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or other jurisdiction.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next
generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency
of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary
human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced
team of technologists, medical device professionals and physicians, and is backed by a strong investor base. The Company is headquartered
in Waltham, Massachusetts.
Forward-Looking Statements
This press release includes "forward-looking
statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform
Act of 1995, including, but not limited to, statements regarding the proposed underwritten offering, including Vicarious Surgical's
expectations with respect to completion, timing and size of the proposed offering, the underwriters' exercise of the option to purchase
additional shares, and the use and application of the estimated net proceeds. The Company's actual results may differ from
its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions
of future events. All statements other than statements of historical facts contained herein are forward-looking statements that reflect
the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that
could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are
outside Vicarious Surgical's control and are difficult to predict. Factors that may cause such differences include, but are not
limited to: market conditions at the time of the proposed offering, the ability to recognize the benefits of Vicarious Surgical's
business combination, which may be affected by, among other things, competition and its ability to grow and manage growth profitably and
retain its key employees; the ability to maintain the listing of Vicarious Surgical's Class A common stock on the New York Stock
Exchange; the success, cost and timing of Vicarious Surgical's product and service development activities; the regulatory clearance,
authorization or approval, commercialization and adoption of Vicarious Surgical's initial product candidates and the success of
Vicarious Surgical's single-port surgical robot, called the Vicarious Surgical System, and any of Vicarious Surgical's future
product candidates and service offerings; the potential attributes and benefits of the Vicarious Surgical System and any of Vicarious
Surgical's other product and service offerings once commercialized; Vicarious Surgical's ability to obtain and maintain regulatory
clearance, authorization, or approval for the Vicarious Surgical System and its product and service offerings on the timeline Vicarious
Surgical expects, and without unexpected restrictions and limitations of any authorized product or service offering; changes in U.S. and
foreign laws; Vicarious Surgical's ability to identify, in-license or acquire additional technology; Vicarious Surgical's
ability to maintain its license agreements and manufacturing arrangements and scale manufacturing of the Vicarious Surgical System and
any future product candidates to commercial quantities; Vicarious Surgical's ability to compete with other companies currently marketing
or engaged in the development of products and services for use in ventral hernia repair procedures and additional surgical applications,
as well as with the use of open surgeries; the size and growth potential of the markets for the Vicarious Surgical System and any of Vicarious
Surgical's future product and service offerings, and the ability of each to serve those markets once commercialized, either alone
or in partnership with others; Vicarious Surgical's estimates regarding expenses, future revenue, capital requirements, cash runway
and needs for additional financing; Vicarious Surgical's ability to raise financing in the future; Vicarious Surgical's financial
performance; Vicarious Surgical's intellectual property rights and its ability to protect or enforce these rights, and the impact
on our business, results and financial condition if Vicarious Surgical is unsuccessful in doing so; and Vicarious Surgical's ability
to address economic downturns and political and market conditions beyond the control of Vicarious Surgical and their potential to adversely
affect Vicarious Surgical's business, financial condition and results of operations, including, but not limited to, increasing Vicarious
Surgical's expenses and cost of capital and adversely impacting its supply chain. Vicarious Surgical cautions that the foregoing
list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which
speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or
circumstances on which any such statement is based.
Vicarious Surgical Contact: